Kazia Therapeutics - ADR opened higher at $7.50, compared with its previous close of $7.43. In the last trading session, the stock traded between $6.90 and $7.65. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Kazia Therapeutics - ADR is now worth
$ 1.20
Resulting in a loss of
$ 98.80 (98.80%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.56 (-7.59%)
Day High
$7.65
Day Low
$6.90
Day Open
$7.50
Prev Close
$7.43
Volume
1,55,945
1W Return
-14.60%
1M Return
-21.19%
3M Return
-50.62%
6M Return
-51.30%
1Y Return
-10.37%
Market Cap ($ Mn)
105
PE Ratio
-
PB Ratio
4.95
PEG Ratio
-
ROE
-
ROCE
625.30%
EPS (TTM)
-
1 Week
-14.60%
1 Month
-21.19%
3 Months
-50.62%
6 Months
-51.30%
9 Months
30.53%
Guggenheim initiates Kazia Therapeutics with Buy rating, $35 target
Guggenheim analyst Paul Jeng initiated coverage on Kazia Therapeutics. The firm assigned a Buy rating to the stock. A price target of $35 was announced for the shares.
22 days agoKazia earns $2 million milestone as Paxalisib epilepsy trial begins
Sovargen dosed the first patient in a Phase 1b/2a trial for paxalisib. The event triggers a $2 million development milestone payment to Kazia. Paxalisib is being evaluated for intractable epilepsy linked to FCD T2 and TSC. Kazia retains oncology focus while earning royalties from CNS partnerships.
1mo agoBTIG maintains Buy on Kazia Therapeutics, raises PT to $40
BTIG maintains a Buy rating on Kazia Therapeutics (NASDAQ: KZIA). Price target raised to $40 from the previous level of $34. Analyst Kambiz Yazdi leads the recommendation update.
2mo agoKazia Therapeutics paxalisib cuts tumor burden 52% in preclinical colorectal cancer study
Paxalisib monotherapy reduced tumor burden by 52% (p=0.035) in MSS/pMMR colorectal cancer models. Combination with immunotherapy drove an additional 50% tumor volume reduction (p=0.022). No treatment-related toxicity observed in either preclinical study. Kazia plans to advance paxalisib into a Phase 2 clinical trial.
2mo agoKazia Therapeutics expands paxalisib trial to HR+/HER2- breast cancer
Preclinical data shows paxalisib resensitizes CDK4/6 inhibitor-resistant tumors to standard-of-care therapy. Company expanding ongoing TNBC trial to evaluate paxalisib in HR+/HER2- advanced breast cancer. Trial design includes three arms: paxalisib plus fulvestrant, with palbociclib, versus standard-of-care. First patient enrollment expected by year-end 2026. Full enrollment targeted for end of 2027.
2mo agoKazia Therapeutics closes oversubscribed $40M offering with milestone-linked warrants
Kazia Therapeutics closed its oversubscribed public offering, raising $40 million in upfront gross proceeds. The deal includes Series A and B warrants exercisable at premiums of 15% and 25% to the offering price. Total potential proceeds could reach $120 million if all milestone-linked warrants are exercised in full. Proceeds will fund clinical development of paxalisib in breast cancer and colorectal cancer indications.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Kazia Therapeutics - ADR is now worth
$ 1.20
Resulting in a loss of
$ 98.80 (98.80%)
Note: Past profits do not guarantee future returns.
